Use of serum CA-125 in monitoring patients with uterine sarcoma. A preliminary report.
Elevated preoperative serum CA-125 levels were present in three of four patients (75%) with Stage I uterine sarcoma found to have extrauterine spread of disease at laparotomy as well as five of seven (71%) patients with clinically advanced and recurrent uterine sarcoma. Serial levels during chemotherapy inconsistently reflected response to treatment and proved to have limited clinical value.
Patsner
B
B
Department OB/GYN, SUNY at Stony Brook, School of Medicine 11794-8091.
Mann
W J
WJ
D000951:Antigens, Neoplasm / Q000032:analysis*; D015295:Antigens, Tumor-Associated, Carbohydrate; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007813:Laparotomy; D008297:Male; D008991:Monitoring, Physiologic; D009361:Neoplasm Invasiveness / Q000276:immunology; D009364:Neoplasm Recurrence, Local / Q000276:immunology; D009367:Neoplasm Staging; D012509:Sarcoma / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery; D014594:Uterine Neoplasms / Q000188:drug therapy / Q000276:immunology* / Q000601:surgery
D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate